OBIO NASDAQ
Credit Risk of going bust: higher than 64% of companies Debt: 17.5% of company value Bonds: none of note held by US funds details ▾
If the stock fell to about $0.14 (down 98%), Orchestra BioMed Holdings, Inc. would be worth roughly what it owes.
Total debt $70.8M against a stock market value of $333.6M.
Distance to default 3.87 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $34.7M (short-term plus half of long-term), stock volatility 63.4%; Altman Z'' -8.87. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
New Hope, PA 18938
US
Orchestra BioMed Holdings, Inc. operates as an innovative company in the biomedical sector. Its leading product candidates are BackBeat Cardiac Neuromodulation Therapy (CNT), designed to manage hypertension, and the Virtue Sirolimus AngioInfusion Balloon (SAB), aimed at treating atherosclerotic artery disease. The company's offerings also encompass FreeHold retractors, which are solutions for minimally invasive surgical procedures. Orchestra BioMed has formed key alliances to advance its products: a strategic collaboration with Medtronic focuses on developing and commercializing BackBeat CNT for pacemaker-indicated patients suffering from hypertension. Additionally, a partnership with Terumo Corporation is dedicated to the development and market introduction of Virtue SAB for artery disease. The company's headquarters are located in New Hope, Pennsylvania.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Sherman Darren | S-Sale | 15,000 | $6.36 | 2026-10-01 |
| Hochman David P | F-InKind | 3,283 | $5.81 | 2026-09-10 |
| Hochman David P | F-InKind | 3,283 | $5.81 | 2026-09-10 |
| Hochman David P | P-Purchase | 10,000 | $4.79 | 2026-09-03 |
| Sherman Darren | S-Sale | 15,000 | $4.94 | 2026-09-01 |